Please login to the form below

Not currently logged in

FDA rejects Merck muscle relaxant drug once again

Regulator still has hypersensitivity concerns about Bridion

Merck & CoMerck & Co's muscle relaxant Bridion has been available in the EU for five years, but the company has once again failed to convince the FDA that it should reach the US market.

Bridion (sugammadex sodium) has been turned down for the second time by the US regulator, this time because of questions surrounding a trial of the drug's tendency to cause hypersensitivity reactions that was requested by the FDA when it turned Bridion down for the first time in 2008.

Sugammadex is used to reverse the effects of muscle relaxants given during surgery, such as rocuronium or vecuronium, and is claimed to help patients come out of anaesthesia more quickly and with fewer side effects than competing agents.

The latest complete response letter (CRL) from the FDA has "raised concerns about operational aspects of [the] hypersensitivity study", according to Merck, which said it was still hoping to bring the drug to hospitals, surgeons, anaesthesia professionals and patients in the US.

The FDA recently conducted an audit of the clinical trial site that carried out the hypersensitivity study, and the findings of the inspectors prompted the agency to cancel an advisory committee meeting due to be held in July.

Bridion is already a useful earner for Merck, bringing in $260m last year but well shy of the $500m-plus analysts expect the drug can make if it wins approval in the US. However, the delay has damaged its prospects by allowing competing drugs - notably Flamel's Bloxiverz (neostigmine) – to reach the market first.

Sugammadex is currently marketed in more than 50 countries other than the US, and more than 5m vials have been sold as of June 2013, said the firm.

The latest setback comes as Merck is in the process of revamping its R&D operations under the leadership of Roger Perlmutter, who replaced former R&D head Peter Kim earlier this year after disappointments such as the failure of cholesterol drug Tredaptive (extended-release niacin/laropiprant).

Setbacks have continued to dog Merck since then, including a knockback for much-anticipated insomnia treatment suvorexant by the FDA in July and a delay in the filing of osteoporosis treatment odanacatib, and some investors have called for an acceleration in the company's R&D restructuring plans to reduce costs and boost productivity.

Article by
Phil Taylor

24th September 2013

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Spotlight interview: 15 minutes on insights and market research in pharma
Neil Rees, Head of Research, OPEN Health Patient & Brand Communication takes 15 minutes to answer some key questions on insights and market research in pharma...
WHITE PAPER: The increasing importance of clinical trial marketing advertising in patient recruitment
Learn why advertising is more important than ever in clinical studies...
The 'winner takes all' pricing game
Tendering has long been common in healthcare for medical devices and diagnostics; the Gulf Cooperation Council and the Jamaica Commodity Trading Company have been using pharmaceutical tendering since the 1970s....